First-in-Human gene therapy trial aims to fix faulty heart genes
NCT ID NCT07137338
Summary
This is a very early study testing the safety of a new gene therapy for adults with a specific inherited form of heart muscle weakness (dilated cardiomyopathy). The therapy, called RP-A701, is given as a single intravenous dose and aims to deliver a working copy of a faulty gene (BAG3) to the heart. Researchers will first check if the treatment is safe in 8 patients and look for early signs that it might improve heart function.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DILATED CARDIOMYOPATHY (DCM) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.